# MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial

> **NCT03892785** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 230 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Prednisone treatment
- **DRUG:** Tocilizumab treatment
- **DRUG:** Methotrexate treatment
- **OTHER:** Questionnaires
- **BIOLOGICAL:** Blood samples

## Key facts

- **NCT ID:** NCT03892785
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-27
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03892785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03892785, "MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03892785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*